Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Steddon, S. J.
Right arrow Articles by Cunningham, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steddon, S. J.
Right arrow Articles by Cunningham, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 1965-1967
© 2001 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Vitamin D analogues: how do they differ and what is their clinical role?

Simon J. Steddon, Neil J. Schroeder and John Cunningham

Department of Renal Medicine and Transplantation, Royal London Hospital, Whitechapel, London, UK

Introduction

The development of vitamin D analogues capable of effective parathyroid suppression whilst avoiding undesirable low bone turnover, hypercalcaemia and hyperphosphataemia has received considerable attention over the last decade [1]. Much in vitro and animal work has been undertaken with frustrating disparity emerging between therapeutic potential in the experimental setting and performance in available clinical trials. The biology and, in particular, gene regulatory properties of vitamin D are now more fully understood [2] and provide useful insights into the mechanisms underpinning the selective properties encountered experimentally. The formulation of ‘designer’ compounds possessing distinct physiological characteristics that will afford them an advantage in the clinical arena remains an enticing prospect.

Vitamin D in uraemia

Vitamin D biology
Vitamin D and its metabolites are transported in the circulation by a specific binding protein, vitamin D binding protein (DBP), which is normally present in large excess. Active vitamin D, 1{alpha},25-dihydroxyvitamin D3 (1,25(OH)2D3 or calcitriol), is . . . [Full Text of this Article]

Vitamin D in the pathophysiology of secondary hyperparathyroidism and osteodystrophy
The vitamin D analogues
Clinical experience with the new analogues

Conclusions

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
S. M. Sprague, P. Evenepoel, M. P. Curzi, M. T. Gonzalez, F. E. Husserl, N. Kopyt, L. R. Sterling, C. Mix, and G. Wong
Simultaneous Control of PTH and CaxP Is Sustained over Three Years of Treatment with Cinacalcet HCl
Clin. J. Am. Soc. Nephrol., September 1, 2009; 4(9): 1465 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. B. Drueke and D. A. McCarron
Paricalcitol as Compared with Calcitriol in Patients Undergoing Hemodialysis
N. Engl. J. Med., July 31, 2003; 349(5): 496 - 499.
[Full Text] [PDF]